(Q40460503)

English

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.

scientific article published on July 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

based on heuristic

inferred from title

Giovanni Luca Gravina

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Adriano Angelucci

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

object named as

Mauro Bologna

7

0 references

Carlo Vicentini

object named as

Carlo Vicentini

6

0 references

Danilo Millimaggi

4

object named as

Danilo Millimaggi

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

5

object named as

Paola Muzi

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Claudio Festuccia

1

object named as

Claudio Festuccia

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

115

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

630-640

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Androgen receptor expression is regulated by the phosphoinositide 3-kinase/Akt pathway in normal and tumoral epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.20917

21 January 2018

Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Management of cancer of the prostate

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Molecular basis for the antiandrogen withdrawal syndrome.

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Androgen receptor involvement in the progression of prostate cancer

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

PI3K/Akt and apoptosis: size matters

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Regulation of prostatic growth and function by peptide growth factors

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor.

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Androgen Receptor Gene Amplification and Protein Expression in Recurrent Prostate Cancer

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Establishment of a new prostatic carcinoma cell line (TSU-Pr1).

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Androgenic regulation of growth factor and growth factor receptor expression in the CWR22 model of prostatic adenocarcinoma

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

ErbB receptors: possible therapeutic targets in prostate cancer?

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Second messenger up-regulation of androgen receptor gene transcription is absent in androgen insensitive human prostatic carcinoma cell lines, PC-3 and DU-145.

1 reference

https://opencitations.net/index/api/v1/references/10.1002/IJC.20917

30 December 2023

Identifiers

10.1002/IJC.20917

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40460503&oldid=2041360328"